MT Group Surpasses 5,000 Customized Biospecimen Collections, Reinforcing Its Position as a Leading Specialty CRO for Prospective Human Tissue and Blood Procurement

▤ Summary

MT Group says it has completed more than 5,000 customized biospecimen collections, highlighting its role as a specialty CRO for prospective human tissue and blood procurement. The company positions its consultative collection model as a better fit than off-the-shelf sample sourcing for translational research, biomarker discovery, companion diagnostic development, and liquid biopsy validation. It supports oncology, autoimmune, neurologic, and other disease programs with matched tissue, blood, plasma, and longitudinal specimen architectures. The announcement also reinforces MT Group’s focus on deep clinical annotation, pathologist-reviewed quality control, and customized study design for life sciences sponsors.

▦ Linked Companies